This is Mingyu Jin.
I am making this post to inform you that I will be presenting this week’s seminar (7/2).
The paper I am going to present is “Gut microbiome structure and metabolic activity in inflammatory bowel disease”.
It was published on Nature Microbiology in June 2019.
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract that results from altered interactions between gut microbes and the intestinal immune system. SCFAs can affect host cells by modulating histone deacetylase (HDAC) inhibitory activity, gene expression, cell proliferation, and immune response. In addition, butyrate can protect against colitis by regulating Treg cell production and enhancing antibacterial activity of macrophages
Yet-to-be characterized molecules in the gut metabolome, linked to inflammation and ultimately IBD, may be largely microbially derived or modified.
In this work, they took an unbiased approach, untargeted LC-MS metabolomic profiling and shotgun metagenomic sequencing of stool samples, to identify gut metabolites, microbial species, and microbial enzymes that were differentially abundant (DA) in IBD relative to non-IBD controls.
Many DA metabolites participated in robust associations with DA microbial species and enzymes: suggestive of biological mechanisms relating their abundances.
With possible applications, such as in the field of interactions between metabolites and microbiotas. I believe the findings from this paper surely are interesting.
Please check out the link below to download the full paper.
https://doi.org/10.1038/s41564-018-0306-4
Best regards.
Mingyu Jin.